2025-12-04 - Analysis Report
Okay, let's break down the analysis of Eli Lilly and Co. (LLY).

**1) Return Rate Comparison**

*   **Company Overview:** Eli Lilly and Co. is a pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.
*   **LLY Cumulative Return:** 291.76%
*   **VOO (S&P 500) Cumulative Return:** 100.36%
*   **Divergence:** 207.5 (Relative Divergence: 85.5)

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period analyzed.  The current divergence is substantial, indicating a strong upward trend compared to the overall market.  The relative divergence of 85.5 suggests that the current outperformance is near the higher end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | 11.0%  | 76.1% | -17.0%  | -0.0   | 75.7   |
| 2016-2018  | 39.0%  | 68.9% | 24.0%   | -0.0   | 103.8  |
| 2017-2019  | 41.0%  | 68.9% | 19.0%   | 0.4    | 117.8  |
| 2018-2020  | 34.0%  | 79.8% | 10.0%   | 0.4    | 151.4  |
| 2019-2021  | 53.0%  | 79.8% | 7.0%    | 0.5    | 247.7  |
| 2020-2022  | 64.0%  | 79.8% | 65.0%   | 0.4    | 328.0  |
| 2021-2023  | 125.0% | 78.9% | 124.0%  | 0.2    | 522.6  |
| 2022-2024  | 134.0% | 81.2% | 113.0%  | 0.2    | 692.2  |
| 2023-2025  | 183.0% | 83.5% | 118.0%  | 0.2    | 927.8  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Shows impressive growth, accelerating significantly in recent years.  The CAGR demonstrates very strong returns for investors over these periods.
*   **MDD (Maximum Drawdown):** Indicates the potential downside risk. While the CAGR is impressive, the MDD values are high, suggesting considerable volatility.
*   **Alpha:**  Represents the excess return compared to a benchmark (likely the S&P 500). Recent Alpha values are extremely high, particularly in the 2020-2025 periods, indicating LLY is generating significant returns independent of overall market movements.
*   **Beta:**  Measures the stock's volatility relative to the market. Beta values are generally low (especially recently), suggesting LLY's price is less sensitive to market movements than the S&P 500.  This, combined with high Alpha, is a very positive sign.
*   **Cap(B):**  Market capitalization in billions. Shows a substantial increase in market capitalization, reflecting the company's growth.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 1034.76
*   **Last Market Data:** Price: 1034.91, Previous Close: 1046.12, Change: -1.07
*   **5-day SMA:** 1074.66
*   **20-day SMA:** 1020.27
*   **60-day SMA:** 871.37

**Analysis:** The current price is slightly down compared to the previous close. The 5-day SMA is significantly above the 20-day SMA, which is above the 60-day SMA.  This suggests a recent upward trend, but the current price being below the 5-day SMA might indicate a potential short-term pullback or consolidation.  The short-term moving average is starting to show a downtrend from the recent surge.

**3) Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 60.67
*   **PPO:** -0.65
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent (20 days) Relative Divergence Change:** 1.1 (+) (short-term increase)
*   **Expected Return (%):** 47.1% (Expected excess return compared to S&P 500 if invested long-term)

**Analysis:**

*   **MRI:** A high MRI suggests the market conditions are favorable for investment in LLY.
*   **RSI:** An RSI of 60.67 is nearing overbought territory (typically above 70), but not quite there. It suggests the stock has had strong upward momentum.
*   **PPO:** A negative PPO indicates that the shorter-term moving average is below the longer-term moving average, suggesting a potential downtrend or consolidation in momentum.
*   **Hybrid Signal:** Recommends investing all available cash, reinforcing the positive investment outlook.
*   **Relative Divergence Change:** The short-term increase in relative divergence confirms recent outperformance compared to the S&P 500.
*   **Expected Return:** A high expected return suggests that analysts anticipate continued outperformance by LLY.
*   **Price Change:** The recent price change indicates a small fluctuation which indicates that market is expecting some issue (rebound or decline)

**4) Recent News & Significant Events**

*   **Positive Coverage:** Many articles reaffirm positive outlooks, including "Bernstein Reaffirms Price Target," "BMO Capital Markets Reiterates Buy Rating," and "Eli Lilly Stock Now 3.5% Cheaper, Time To Buy." These reinforce the stock's attractiveness.
*   **GLP-1 Market:**  The article about "GLP-1 Price Cuts" suggests a potential shift in the market landscape that could impact LLY, depending on its positioning and strategy. Monitoring this is important.
*   **Stock Split Speculation:**  The article about a potential "Stock Split" often signals confidence in future growth and makes the stock more accessible to a wider range of investors.
*   **Negative coverage:** "Eli Lilly Stock Slides" hints that the price change fluctuation may have started.
**4-2) Analyst Opinions**

*   **Consensus:** The analyst consensus is strongly positive, with a "Buy" rating and a mean score of 1.77.
*   **Target Prices:** The average target price of $1040.89 is slightly above the current price.
*   **Recent Rating Changes:** No new rating changes reported
*   **Stock Price:** Analysts believe that the company's stock price can go higher in general.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-10-30 | 6.22 | 17.60 B$  |
| 2025-08-07 | 6.3  | 15.56 B$  |
| 2025-05-01 | 3.07 | 12.73 B$  |
| 2024-10-30 | 1.08 | 11.44 B$  |
| 2025-10-30 | 1.08 | 11.44 B$  |

**Analysis:**

*   **EPS (Earnings Per Share):** EPS has shown strong growth in recent quarters.
*   **Revenue (매출):**  Revenue has also shown strong growth, indicating increased sales and market demand.
*   **Error date:** There is an error with duplicated date (2025-10-30) which could indicate to previous data or other type of issue.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.60B   | 82.91%        |
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |

**Analysis:** Revenue has consistently increased over the past five quarters. Profit margins are very high and stable, suggesting strong pricing power and efficient operations.

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30   | $23.79B   | 23.46%   |
| 2025-06-30   | $18.27B   | 30.98%   |
| 2025-03-31   | $15.76B   | 17.50%   |
| 2024-12-31   | $14.19B   | 31.07%   |
| 2024-09-30   | $14.24B   | 6.81%    |

**Analysis:**

*   **Equity:** Equity has been increasing, indicating the company is building its net worth.
*   **ROE (Return on Equity):** ROE fluctuates, with a dip in 2025-03-31 and 2024-09-30.
**7) Comprehensive Analysis**

Eli Lilly and Co. (LLY) presents a compelling picture of strong growth and outperformance.  The stock has significantly outperformed the S&P 500, driven by substantial revenue and earnings growth and high profit margins.

*   **Strengths:**
    *   High CAGR and Alpha, demonstrating strong independent performance.
    *   Low Beta, suggesting lower volatility relative to the market.
    *   Positive analyst consensus and target prices.
    *   Strong revenue and earnings growth.
    *   High and stable profit margins.
    *   Positive MRI.
    *   Stock split speculation (signals confidence).

*   **Weaknesses/Risks:**
    *   High Maximum Drawdown, indicating potential volatility.
    *   Recent price change and PPO may hint at short-term pullback.
    *   Possible error with duplicated date on EPS report.
    *   The article about "GLP-1 Price Cuts" suggests a potential shift in the market landscape that could impact LLY, depending on its positioning and strategy.
*   **Recommendation:** The data generally supports a positive outlook for LLY, but there are a few caveats. It appears the stock may be entering a short-term pullback, and the news concerning GLP-1 price cuts warrants further monitoring. The analyst opinions are that the price can go higher overall.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.